Regular Article
Prediction of the Intestinal First-pass Metabolism of CYP3A and UGT Substrates in Humans from in vitro Data

https://doi.org/10.2133/dmpk.DMPK-11-RG-034Get rights and content

Summary:

This study aimed to establish a practical and simplified method of predicting intestinal availability in humans (Fg,human) at the drug discovery stage using in vitro metabolic clearance values and permeability clearance values. A prediction model for Fg,human of 19 CYP3A substrates and 5 UGT substrates was constructed based on the concept that the permeability clearance values mean the permeability across the basal membrane with a pH of 7.4 on both sides. Permeability clearance values were obtained by parallel artificial membrane permeability assay (PAMPA) at pH 7.4. PAMPA is widely used in the pharmaceutical industry as the earliest primary screening stage and enables estimation of the kinetics of transport by passive diffusion. For CYP3A substrates, the metabolic clearance was obtained from in vitro intrinsic clearance values in human intestinal or hepatic microsomes (CLint,HIM or CLint,HLM, respectively). Using metabolic clearances corrected by the ratio of CLint,HIM to CLint,HLM, HLM showed equivalent predictability to that of HIM for CYP3A substrates. For UGT substrates, the clearance was obtained from alamethicin-activated HIM using one incubation with both NADPH and UDPGA cofactors. The method proposed in this study could predict Fg,human for the compounds investigated and represents a simplified method based on a new concept applicable to lower permeability compounds.

References (41)

  • M. Mistry et al.

    Quantitation of extrahepatic metabolism

    Pulmonary and intestinal conjugation of naphthol. Drug Metab. Dispos.

    (1985)
  • J. Yang et al.

    Prediction of intestinal first-pass drug metabolism

    Curr. Drug Metab.

    (2007)
  • M. Gertz et al.

    Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data

    Drug Metab. Dispos.

    (2010)
  • H. Nishimuta et al.

    Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys

    Drug Metab. Dispos.

    (2010)
  • A. Avdeef

    The rise of PAMPA

    Expert Opin. Drug Metab. Toxicol.

    (2005)
  • R. Zuber et al.

    Cytochromes P450 and experimental models of drug metabolism

    J. Cell. Mol. Med.

    (2002)
  • M.F. Paine et al.

    The human intestinal cytochrome P450 “PIE”

    Drug Metab. Dispos.

    (2006)
  • J.A. Williams et al.

    Drugdrug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios

    Drug Metab. Dispos.

    (2004)
  • R.H. Tukey et al.

    Human UDP-glucuronosyltransferases: metabolism, expression, and disease

    Annu. Rev. Pharmacol. Toxicol.

    (2000)
  • M.B. Fisher et al.

    In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin

    Drug Metab. Dispos.

    (2000)
  • Cited by (50)

    • Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings

      2017, Journal of Pharmaceutical Sciences
      Citation Excerpt :

      Therefore, the slight exposure decrease (23%-24%) in etoposide and saquinavir when co-administered with grapefruit juice (100 mL single dose) and quercetin (500 mg 3 times daily for 8 days), respectively, could be caused by intestinal inhibition of OATPs. It should be noted that intestinal inhibition of CYP3A by grapefruit juice and quercetin could not be ruled out, based on the observations that both etoposide and saquinavir are substrates of CYP3A in vitro.110,149-170 Interestingly, quercetin also induced CYP3A, with a 24% reduction in exposure of co-administered midazolam, a CYP3A probe substrate,171 likely through pregnane X receptor activation.172

    View all citing articles on Scopus
    View full text